EA201891085A1 - Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания - Google Patents
Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболеванияInfo
- Publication number
- EA201891085A1 EA201891085A1 EA201891085A EA201891085A EA201891085A1 EA 201891085 A1 EA201891085 A1 EA 201891085A1 EA 201891085 A EA201891085 A EA 201891085A EA 201891085 A EA201891085 A EA 201891085A EA 201891085 A1 EA201891085 A1 EA 201891085A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- ctc
- heterogeneity
- cells
- characterize
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70589—CD45
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Это описание относится к способу детекции гетерогенности заболевания у пациента с злокачественной опухолью, включающему (a) проведение прямого анализа, включающего иммунофлуоресцентное окрашивание и морфологическую характеризацию ядросодержащих клеток в образце крови, полученном от пациента, для идентификации и подсчета циркулирующих клеток опухолей (CTC); (b) выделение CTC из образца; (c) индивидуальную характеризацию геномных параметров для получения геномного профиля для каждой из CTC и (d) определение гетерогенности заболевания у пациента с злокачественной опухолью на основании этого профиля. В некоторых вариантах осуществления злокачественная опухоль представляет собой рак предстательной железы. В некоторых вариантах осуществления рак предстательной железы является невосприимчивым к гормонам.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562250422P | 2015-11-03 | 2015-11-03 | |
PCT/US2016/059877 WO2017079139A1 (en) | 2015-11-03 | 2016-11-01 | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201891085A1 true EA201891085A1 (ru) | 2018-11-30 |
Family
ID=58662599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891085A EA201891085A1 (ru) | 2015-11-03 | 2016-11-01 | Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания |
Country Status (9)
Country | Link |
---|---|
US (2) | US20180321247A1 (ru) |
EP (1) | EP3371327A4 (ru) |
JP (1) | JP7043412B2 (ru) |
CN (2) | CN115341033A (ru) |
AU (2) | AU2016348401A1 (ru) |
CA (1) | CA3004150A1 (ru) |
EA (1) | EA201891085A1 (ru) |
IL (1) | IL259093A (ru) |
WO (1) | WO2017079139A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107422127A (zh) | 2009-10-21 | 2017-12-01 | 斯克里普斯研究所 | 用非稀有细胞检测稀有细胞的方法 |
EP3100047B1 (en) | 2014-01-27 | 2021-08-11 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
EP3108246B1 (en) | 2014-02-21 | 2019-10-09 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014047285A1 (en) * | 2012-09-19 | 2014-03-27 | Paraskevi Giannakakou | Identifying taxane sensitivity in prostate cancer patients |
WO2014165785A2 (en) | 2013-04-05 | 2014-10-09 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
CN106062561B (zh) * | 2013-09-30 | 2021-11-09 | 斯克利普斯研究院 | 为了监测前列腺癌患者中的肿瘤进化进行循环肿瘤细胞的基因型和表型分析 |
WO2015073896A2 (en) * | 2013-11-15 | 2015-05-21 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
WO2015106341A1 (en) * | 2014-01-17 | 2015-07-23 | Ontario Institute For Cancer Research (Oicr) | Biopsy-driven genomic signature for prostate cancer prognosis |
EP3100047B1 (en) * | 2014-01-27 | 2021-08-11 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
EP3100052B1 (en) * | 2014-01-30 | 2021-03-10 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
-
2016
- 2016-11-01 JP JP2018543010A patent/JP7043412B2/ja active Active
- 2016-11-01 AU AU2016348401A patent/AU2016348401A1/en not_active Abandoned
- 2016-11-01 EA EA201891085A patent/EA201891085A1/ru unknown
- 2016-11-01 EP EP16862785.9A patent/EP3371327A4/en active Pending
- 2016-11-01 CA CA3004150A patent/CA3004150A1/en active Pending
- 2016-11-01 US US15/773,154 patent/US20180321247A1/en not_active Abandoned
- 2016-11-01 CN CN202210906018.2A patent/CN115341033A/zh active Pending
- 2016-11-01 WO PCT/US2016/059877 patent/WO2017079139A1/en active Application Filing
- 2016-11-01 CN CN201680078293.2A patent/CN108603233A/zh active Pending
-
2018
- 2018-05-02 IL IL259093A patent/IL259093A/en unknown
-
2021
- 2021-01-06 US US17/142,767 patent/US20210405055A1/en active Pending
-
2023
- 2023-01-24 AU AU2023200364A patent/AU2023200364A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN115341033A (zh) | 2022-11-15 |
JP7043412B2 (ja) | 2022-03-29 |
WO2017079139A1 (en) | 2017-05-11 |
AU2023200364A1 (en) | 2023-02-23 |
EP3371327A4 (en) | 2019-07-03 |
EP3371327A1 (en) | 2018-09-12 |
IL259093A (en) | 2018-06-28 |
JP2018534595A (ja) | 2018-11-22 |
CA3004150A1 (en) | 2017-05-11 |
CN108603233A (zh) | 2018-09-28 |
AU2016348401A1 (en) | 2018-05-24 |
US20180321247A1 (en) | 2018-11-08 |
US20210405055A1 (en) | 2021-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891571A1 (ru) | Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания | |
EA201691505A1 (ru) | Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc) | |
EA201691496A1 (ru) | Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток | |
EA201691352A1 (ru) | Диагностика рака легкого с помощью циркулирующих опухолевых клеток | |
EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
MX2018008421A (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
HK1249553A1 (zh) | 在血液樣本中的循環腫瘤細胞的數字分析 | |
EA201691499A1 (ru) | Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям | |
MX2015014474A (es) | Dispositivo de recogida de fluidos biologicos y sistemas de recogida y ensayo de fluidos biologicos. | |
NZ607282A (en) | Method for using gene expression to determine prognosis of prostate cancer | |
WO2011112903A3 (en) | Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients | |
EA201891085A1 (ru) | Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания | |
GB2545361A (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
MX2018009254A (es) | Metodos para evaluar el riesgo de desarrollar cancer colorrectal. | |
MX2019012260A (es) | Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga. | |
EP3492607A3 (en) | Urinary mirnas for the in vitro diagnosis of bladder cancer | |
EA201691168A1 (ru) | Способы исследования бета-глюкана | |
EA201890816A1 (ru) | Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc) | |
BR102015015096A2 (pt) | método de detecção in vitro de câncer de tireoide em um paciente, método in vitro de diferenciação entre câncer de tireoide e tecido de tireoide normal ou de lesões benignas de tireoide, uso de um conjunto de genes, método de obtenção de dados para direcionamento do tratamento do cancer de tireoide, kit laboratorial e dispositivo para classificar uma amostra biológica de glândula tireoide como maligna ou benigna | |
EA201690995A1 (ru) | Способы обнаружения и количественного анализа циркулирующих эндотелиальных клеток | |
RU2013140122A (ru) | Способ диагностики рака молочной железы | |
WO2016018524A8 (en) | E2f4 signature for use in diagnosing and treating breast and bladder cancer | |
UA90720U (ru) | Способ определения генотоксического воздействия на клетки организма | |
Zhang et al. | Application and development of point-of-care testing in domain of tumor markers | |
WO2015193738A3 (en) | Methods and biomarkers for analysis of colorectal cancer |